Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Calcium Nanoparticles to Enhance Immuno-Radiotherapy

Award Number: R01CA299080
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/24/2026
PERIOD OF PERFORMANCE END DATE: 02/28/2031

Group Awards By:

View Award Description

Calcium Nanoparticles to Enhance Immuno-Radiotherapy - Abstract Immune checkpoint blockade has become a cornerstone treatment for many solid tumors. However, not all patients respond effectively to this therapy. To enhance its efficacy, researchers are exploring the combination of radiation and immunotherapy, a strategy known as radio-immunotherapy. Despite its promise, radio- immunotherapy has not consistently demonstrated clinical benefit, in part due to a lack of activated dendritic cells (DCs) within tumors. Among these immune cells, a specific subset known as cDC1s plays a crucial role in antigen cross-presentation to T cells in the tumor-draining lymph nodes (TDLNs) to initiate anti-tumor immune responses. Emerging studies suggest that cDC1s in the TDLNs are also critical targets for immune checkpoint inhibitors. Tumors resistant to immunotherapy or radio-immunotherapy often exhibit low cDC1 levels, and their migration to TDLNs can be impeded by the immunosuppressive tumor microenvironment. This project aims to develop a calcium nanoparticle-based combinatory treatment to enhance radio- immunotherapy by improving both tumor infiltration and TDLN migration of cDC1s. We hypothesize that surface- engineered calcium nanoparticles, termed αCaNPs, can selectively deliver calcium, a key second messenger for immune cell migration, into circulating cDC1s, thereby enhancing their tumor infiltration in response to chemotactic signals. In addition, we anticipate that αCaNPs, by elevating cytosolic calcium levels, will promote cDC1 maturation inside tumors and afferent migration to TDLNs. Under immune checkpoint blockade with PD- L1 antibody, we expect that cDC1s will prime T cells in the TDLNs, leading to clonal expansion and robust anti- tumor immunity. To evaluate the efficacy of this approach, we will use murine models of head and neck squamous cell carcinoma (HNSCC). If successful, our technology could be extended to other cancers currently under intensive clinical investigation for radio-immunotherapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $618,236 )
2026	2026	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.	310 E CAMPUS RD RM 409	ATHENS	GA	30602	CLARKE	USA	Cancer Treatment Research	000	1	3/24/2026	NEW	$618,236
														Subtotal = $618,236

Grand Total All Awards = $618,236

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Calcium Nanoparticles to Enhance Immuno-Radiotherapy

Award Number: R01CA299080

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/24/2026

PERIOD OF PERFORMANCE END DATE: 02/28/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer